Universal HLA-E - targeted HPV immunotherapy platform
This technology comprises antibodies, TCRs, and CAR-T cells targeting HPV-derived peptides presented by the non-polymorphic HLA-E molecule. It enables universal, cell-mediated immunotherapies for treating persistent HPV infection and HPV-driven cancers, independent of patient HLA type.
Applications: Cervical Cancer treatment, HPV-associated solid tumour, persistent HPV infection
| Features | Benefits |
|---|---|
| HLA-E–driven universal targeting | Exploiting the conserved nature of HLA-E overcomes the genetic diversity constraints of classical HLA molecules, enabling consistent therapeutic activity across patients |
| Addresses unmet need in persistent HPV infection | Unlike prophylactic vaccines, this approach targets infected and transformed cells directly. It is specifically designed for patients with established HPV infection or HPV-driven malignancies, where current vaccines are ineffective |
| Multi-modality therapeutic platform | The IP spans antibodies, soluble receptors, CAR-T cells, and engineered TCRs, as well as nucleic acids, vectors, and cell therapies. This enables multiple product formats and flexible commercialisation pathways |
| Designed for scalable cell and gene therapy | Compatibility with viral and non-viral vectors supports established CAR-T and TCR-T manufacturing workflows, accelerating clinical translation and industrial scalability |
| Broad oncology and infectious disease reach | Applicable across HPV-associated cancers, including cervical, head and neck, anal, and other anogenital cancers as well as persistent viral infections, expanding both clinical and commercial impact |
Available For
- Co-development
- Consulting
- Licensing